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E-mail address: sbhwang@hallym.ac.kr (S.B. HwanTo investigate the molecular mechanisms underlying interferon alpha (IFNa) treatment failure in
hepatitis C virus (HCV) patients with chronic hepatitis, we aimed to develop an IFNa-resistant clone
of HCV. By treating JFH-1-infected Huh7.5 cells with a prolonged low-dose treatment of IFNa, we
selected a clone of HCV that survived against 100 U/ml of IFNa. By genetic analysis of this clone,
we found four substitution mutations in the C-terminal coding sequence of non-structural 5A
(NS5A). By introducing these four mutations into wild-type JFH-1, we established a new HCV clone
that acquired IFNa resistant phenotype. These data suggest that four amino acid substitutions in
NS5A are involved in IFNa resistance and thus this newly established HCV may be a useful tool
for elucidating the molecular mechanisms of IFNa resistance in HCV patients.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) infection is a global health problemwith
estimated 170 million carriers [1–4]. HCV is an enveloped, posi-
tive-sense RNA virus classiﬁed in the Hepacivirus genus within
the Flaviviridae family. HCV has been classiﬁed into six major geno-
types and numerous subtypes. Viral genome encodes a large poly-
protein precursor which is posttranslationally cleaved into three
structural (core, E1, and E2) and seven non-structural (p7, NS2 to
NS5B) proteins.
Persistent infection of HCV is a major cause of chronic hepatitis
which progresses to liver cirrhosis, and hepatocellular carcinoma.
Despite its high prevalence, a protective vaccine against HCV is
not yet available. The only licensed therapy for chronic hepatitis
C infection is weekly subcutaneous injection of polyethylene glycol
(PEG)-conjugated interferon alpha (IFNa) given in combination
with daily dose of the guanosine analog ribavirin. The treatment
achieves a sustained virological response (SVR) with signiﬁcant dif-chemical Societies. Published by E
rferon alpha; SVR, sustained
NS5A, non-structural 5A
ch Laboratory of Hepatitis C
ity, 1605-4 Gwanyang-dong,
+82 31 384 5395.
g).ferences between genotypes [5]. Overall, the rate of SVR is approx-
imately 50% in genotype 1 and 70–80% in genotypes 2 and 3 in
patients with chronic HCV infection. SVR is deﬁned as the loss of
detectable HCV RNA during treatment and its continued absence
for at least 6 months after stopping therapy; whereas an early viro-
logical response (EVR) is deﬁned as a decline of the viral load by >2
log10 after 12 weeks of therapy. SVR strongly depends on the early
response to treatment. Patients who do not show EVR are unlikely
to develop SVR [6,7].
To investigate the molecular mechanisms underlying IFNa
resistance in HCV patients with chronic hepatitis, we aimed to gen-
erate the IFNa-resistant HCV clone. Since JFH-1 (genotype 2a) is
the only infectious clone available for cell culture [8], and 20–
30% of patients infected with HCV genotype 2a are still non-
responders for IFNa treatment, we used JFH-1 to generate the
IFNa-resistant HCV clone using cell culture system. JFH-1-infected
huh7.5 cells were treated with 10 U/ml of IFNa for 45 days and fur-
ther treated with 30 U/ml of IFNa for additional 45 days. Four sub-
stitution mutations were found in the C-terminal region of non-
structural 5A (NS5A) protein. We replaced wild-type sequence
with these four mutated amino acids in the genome of JFH-1. This
newly established JFH-1 showed higher resistance to IFNa than
wild-type JFH-1. These results suggest that genetic alterations in
NS5A may contribute to the acquisition of the IFN-resistant pheno-
type in vivo.lsevier B.V. All rights reserved.
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2.1. Cell culture
Huh7.5 cells were grown in Dulbecco’s modiﬁed Eagle medium
(DMEM) supplemented with 10% fetal calf serum (Gibco), non-
essential amino acid, and 100 units/ml penicillin/streptomycin.
For selection of IFNa-resistant HCV clone, 7.5  106 Huh7.5 cells
were electroporated with 10 lg of in vitro transcribed JFH-1 RNA.
At 2 days after electroporation, cells were split into two groups and
continuously subcultured at every other day in the absence or
presence of 10 U/ml of IFNa for 45 days and 30 U/ml of IFNa for
additional 45 days. The presence of HCV was continuously moni-
tored by immunoblot analysis using anti-NS5A antibodies.
2.2. Viral RNA transcription and transfection
JFH-1 RNA genome was generated as described previously [8].
Brieﬂy, the pJFH-1 plasmid was linearized by XbaI digestion. RNA
transcripts were generated (Promega T7 RiboMAX Express kit)
and puriﬁed (Invitrogen Trizol LS) according to the manufacturer’s
protocol. Ten microgram of in vitro-transcribed genomic JFH-1
RNA was mixed with 7.5  106 Huh7.5 cells in 0.4-cm gap cuvette
and electroporated at 300 V and 975 lF using a Bio-Rad Gene Pul-
ser II electroporator. Cells were gently transferred to a culture plate
containing complete media (low glucose DMEM containing 10%
FBS, 100 units/ml penicillin/streptomycin, 2 mM L-glutamine,
1 mM NEAA, and 10 mM HEPES) and grown at 37 C.
2.3. Protein extraction and immunoblot analysis
Cells were lysed in RIPA buffer containing 50 mM Tris–HCl (pH
7.5), 150 mM sodium chloride (NaCl), 1 mM ethylenediaminetetra-
acetic acid (EDTA), 1% non-idet P-40 (NP-40), 0.25% sodium deoxy-
cholate, 1 mM sodium orthovanadate (Na3VO4), 1 mM sodium
ﬂuoride (NaF), 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), and
1 mM b-glycerophosphate for 15 min on ice. The protein concen-
tration was determined by the Bradford assay (Bio-Rad). Equal
amounts of protein were subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS–PAGE) and electrotransferred
to a nitrocellulose membrane. The membrane was blocked in Tris–
buffered saline/Tween (TBST) (20 mM Tris–HCl (pH 7.5), 500 mM
NaCl, and 0.05% Tween 20) containing 5% non-fat dry milk for
1 h and then incubated overnight at 4 C with primary antibodies.
Following three washes in TBST, the membrane was incubated
with secondary antibodies in TBST for 1 h at room temperature.
Proteins were detected using an ECL kit (Elpis Biotech Inc). Rabbit
anti-HCV core antibody has been previously described [9]. Both
HCV NS3 and NS5A antibodies were kindly provided from Dr. BY
Ahn (Korea University, Seoul Korea). ISG15 and GAPDH antibodies
were purchased from Santa Cruz Biotechnology.
2.4. Quantiﬁcation of HCV RNA
Both intracellular and extracellular RNAs were extracted by
using Trizol reagent (Invitrogen) according to the manufacturer’s
instruction. cDNAs were synthesized by reverse transcription using
SuperScript VILOTM cDNA synthesis kit (Invitrogen). The quantita-
tive real-time PCR was done by using an iQ5 multicolor Real-time
PCR Detection system (Bio-Rad) and the primers speciﬁc for HCV
50NTR or b-actin under the following conditions: 15 min at 95 C
followed by 40 cycles of 95 C for 20 seconds, 55 C for 20 s,
72 C for 20 s. Seventy one cycles of 10 seconds with 0.5 C temper-
ature increments from 60 to 95 C were used for the melting
curves. HCV 50NTR sequence was cloned into the T–A vector(RBC) and used as a standard for real-time PCR. The standard
was run in parallel with the test samples and the absolute RNA
copy number was determined based on standard curve.
2.5. Sequencing of HCV genome
For sequencing of the HCV genome, intracellular RNAs were ex-
tracted from JFH-1 infected Huh7.5 cells by using the Trizol re-
agent (Invitrogen). cDNAs were synthesized as described above
and used for PCR to amplify ﬁve overlapping fragments spanning
almost the entire JFH-1 genome from nucleotide number 76–
9255. PCR products were puriﬁed by agarose gel electrophoresis
and analyzed for sequencing.3. Results
3.1. Identiﬁcation of IFNa-resistant HCV clone using a cell culture
system
To investigate the molecular mechanisms underlying IFNa
treatment failure in HCV patients with chronic hepatitis, we aimed
to develop IFNa-resistant clone of JFH-1 strain (genotype 2a) of
HCV. Huh7.5 cells were transfected with JFH-1 RNA by electropor-
ation. At 2 days post-transfection, cells were treated with IFNa at
the ﬁnal concentration of 10 U/ml. Cells were sub-cultured at every
other day in the presence of 10 U/ml of IFNa for 45 days and 30 U/
ml of IFNa for additional 45 days. Huh7.5 cells transfected with
JFH-1 RNA with no IFNa treatment were grown in parallel as a con-
trol. During prolonged cultivation, the presence of HCV in Huh7.5
cells was continuously conﬁrmed by immunoblot analysis using
NS5A antibodies (data not shown). JFH-1 viruses cultured for
90 days were then examined for the susceptibility to IFNa. For this
purpose, Huh7.5 cells infected with JFH-1 viruses were treated
with different concentrations of IFNa for 2 days. As shown in
Fig. 1A, IFNa inhibited HCV NS5A protein expression in a dose
dependent manner in both groups. However, JFH-1 viruses that
have been cultured in the presence of IFNa for 90 days (Fig. 1A,
lanes 4–6) showed higher protein expression level of NS5A than
IFNa-untreated control HCV (top panel). This was further con-
ﬁrmed by immunoblot analysis using anti-NS3 (Fig. 1A, lanes 4–6
in 2nd panel) and anti-HCV core antibodies (data not shown). It
was noteworthy that these viruses are highly resistant to the high
concentration of IFNa (Fig. 1A, lane 6). We also examined the intra-
cellular HCV RNA level by real time RT-PCR. HCV RNAs were com-
pletely eliminated at 100 u/ml of IFNa in untreated control cells
(Fig. 1B, lane 3 in upper panel). On the other hand, viral RNA level
was still high in cells treated with IFNa for 90 days (Fig. 1B, lanes
5–6 in upper panel). The normalized data further conﬁrmed that
JFH-1 viruses that had been survived for 90 days in the presence
of IFNa acquired IFNa resistance (Fig. 1B, lanes 5–6 in lower panel).
3.2. Mutations were occurred in NS5A region of IFNa-resistant HCV
clone
To examine whether any mutations in JFH-1 genome were
responsible for IFNa-resistance, we compared genome sequence
among parental wild-type, untreated control, and IFNa-treated
HCV RNA. Total HCV genome was divided into 5 overlapping frag-
ments spanning from nucleotide number 76–9255 of JFH-1 for
sequencing (Fig. 2A). Intracellular RNAs were extracted from cells
of both untreated and IFNa-treated group and cDNAs were ampli-
ﬁed. After sequencing ﬁve fragments, the determined nucleotide
and amino acid sequences were compared with those of the origi-
nal JFH-1. Sequencing data showed that there were 10 point muta-
tions in the C-terminal coding region of NS5A. There was no
Fig. 1. Identiﬁcation of IFNa-resistant HCV clone at 90 days after IFNa treatment. (A) Huh7.5 cells were infected with JFH-1 and divided into two groups: one group was left
untreated with IFNa for 90 days and the other group was treated with 10 U/ml of IFNa for 45 days and then switched to 30 U/ml of IFNa for additional 45 days. To determine
IFNa susceptibility, both groups of HCV-infected Huh7.5 cells were treated with the indicated concentrations of IFNa for 2 days and protein expressions were analyzed by
immunoblot analysis. (B) Intracellular RNAs isolated from (A) were analyzed by real time RT-PCR (upper panel). Normalized data in either IFNa-untreated group (Lanes 1–3)
or IFNa-treated group (lanes 4–6) are shown in lower panel.
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tions were commonly found in the JFH-1 genome of both untreated
and IFNa-treated cells (S448W, S450W, S457P, D461N, T462P, and
C465G). Importantly, four amino acid substitutions were found
only in the sequence of IFNa-treated JFH-1 (A445P, Q458G,
Q459G, and V464L). We speculated that these four mutations in
HCV genome were occurred under the long-term selection pres-
sure to acquire the IFNa resistance.
3.3. Establishment of IFNa-resistant HCV clone
To verify whether substitution mutations detected in NS5A
were responsible for the resistance of IFNa, we introduced these
mutations into the wild-type JFH-1 genome. Intracellular RNAs
were extracted from either IFN-untreated or IFNa-treated cells, fol-
lowed by RT-PCR to amplify two fragments, including nucleotide
number 4165–6258 and 6117–7893. Assembly PCR was performed
to obtain larger fragment encompassing nucleotide number 4165–
7893. Both wild-type pJFH-1 plasmid and PCR products were di-
gested by NsiI and BsrGI (Fig. 2A). PCR products containing muta-
tions were inserted into the corresponding sites of pJFH-1
plasmid. The resultant recombinant plasmid contained either six
adaptive mutations in IFNa-untreated recombinant pJFH-1plasmid
or ten mutations in IFNa-treated recombinant pJFH-1 plasmid. We
then examined the effects of this new JFH-1 genome on HCV
production and IFNa susceptibility. HCV RNA genomes were syn-
thesized in vitro and electroporated into Huh7.5 cells. As demon-
strated in Fig. 3A, HCV production levels were indistinguishable
between cells transfected with IFNa-untreated and treated RNA
genome. Viruses harvested from culture supernatants derived from
cells infected with either IFNa-untreated or treated HCV were used
to re-infect Lunet Huh7.5 cells. Virus-infected cells were then trea-
ted with different concentrations of IFNa to assess the degree of
IFNa resistance. Fig. 3B showed that HCV containing six adaptive
mutations are susceptible to IFNa in a dose dependent manner.
However, HCV containing ten mutations are highly resistant toIFNa even at high concentration of IFNa as demonstrated by
NS5A protein level. This was further conﬁrmed by intracellular
HCV RNA (Fig. 3C) and extracellular HCV RNA levels (Fig. 3D). To
examine whether IFNa signaling was altered in IFNa-resistant
JFH-1 HCV, ISG15 expression level was analyzed by immunoblot
analysis. As shown in Fig. 3B (middle panel), ISG15 expression
was induced by IFNa in a dose dependent manner. However, there
was no difference in ISG15 expression level between untreated
control and IFNa-treated group. These data suggested that HCV
might acquire the IFNa resistance other than canonical IFNa sig-
naling pathway. Collectively, these data suggest that four substitu-
tion mutations that have been found only in IFNa-treated HCVmay
contribute to the IFNa resistance.
4. Discussion
To elucidate the molecular mechanisms underlying IFNa resis-
tance in HCV patients with chronic hepatitis C, we generated the
IFN-resistant phenotype of JFH-1 strain of HCV. Since HCV might
be completely eliminated by the long-term culture at high dosage
of IFNa treatment, JFH-1 infected Huh7.5 cells were treated with
low concentration of IFNa (10 U/ml for 45 days and 30 U/ml for
45 days, respectively) for 90 days. We found six adaptive muta-
tions (S448W, S450W, S457P, D461N, T462P, and C465G) in the
HCV genome regardless of IFNa treatment. However, four muta-
tions (A445P, Q458G, Q459G and V464L) were occurred only in
IFNa-treated HCV but not in untreated control HCV. We introduced
these four mutations into the wild-type JFH-1 and investigated the
IFNa resistance. Indeed, JFH-1 containing four mutations had high-
er tolerance to IFNa than parental JFH-1. Because these four amino
acid substitutions were not occurred during the long-term culture
in control cells, these genetic alterations might be occurred during
prolonged IFNa treatment to acquire IFNa resistance. Furthermore,
IFNa-untreated control HCVs were highly sensitive to IFNa treat-
ment, six adaptive mutations occurred in both groups played no
role in IFNa resistance. Namba et al. previously established HCV
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Fig. 2. (A) Sequencing map is illustrated. Total JFH-1 HCV genome was divided into 5 overlapping fragments for sequencing. Both forward and reverse primers in each group
are shown. (B) Genetic analysis of IFNa-resistant HCV genome. Intracellular RNAs were extracted from cells of both untreated and IFNa-treated groups. Five overlapping
fragments spanning from position 76 to 9255 of JFH-1 genome were ampliﬁed. Parental JFH-1, untreated and IFNa-treated HCV sequences are presented for comparison. The
square boxes indicate IFNa resistant mutations in the nucleotide (upper panel) and amino acids (lower panel) sequences. Arrows indicate adaptive mutations. Original
denotes parental JFH-1 sequence.
412 H.T.L. Tran et al. / FEBS Letters 585 (2011) 409–413subgenomic replicon cells possessing IFNa-resistant phenotype
[10]. Because the entire HCV genome has been used in the present
study, we claim that our newly established HCV clone is more suit-
able for studying IFNa resistant mechanisms than previously re-
ported HCV replicon cells bearing IFNa-resistant phenotype [10].
Previous studies have reported that HCV could modulate IFN
signaling to enhance the viral replication [11–14]. Because ISG15
expression level was not altered in both IFNa-untreated and trea-
ted HCV, our data indicated that these mutations were occurred
via the mechanism other than canonical IFNa signaling pathway.
However, our data are not conclusive yet and thus further experi-
ments are required to elucidate the mechanisms of IFNa resis-
tance. In the present study, we successfully established the
IFNa-resistant HCV clone. Four substitution mutations in the
new HCV clone might be occurred under the long selective pres-
sure by IFNa. It was noteworthy that all amino acid substitutions
were occurred only in the NS5A coding sequence. Since these
mutation sites are not overlapped with the IFN sensitive determin-
ing region (ISDR) in NS5A, our data indicate that unknown factorsother than ISDR may be involved in IFNa-resistance in HCV. It may
be plausible that some cellular factors, either alone or in combina-
tion with HCV protein, may play a role in the acquisition of IFNa
resistance. However, we need more IFNa resistant HCV clones
for detailed study because our newly established clone may not
be enough to explain the molecular mechanisms underlying IFNa
resistance in patients with chronic HCV infection. In addition, clin-
ical informative results will further support our ﬁnding that four
amino acids in the NS5A are truly conserved in IFN non-responders
of HCV patients. Taken together, we obtained an IFNa resistant
HCV clone and this newly established HCV may be a useful tool
for elucidating the molecular mechanisms of IFNa resistance often
found in HCV patients.Acknowledgments
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